In this webinar, we describe current research efforts being developed in the FDA’s Division of Applied Regulatory Science (CDER), for evaluating microphysiological systems while considering their potential use in drug development.
Staff Fellow (Biological Scientist)
Watch this webinar to learn:
Microengineered in vitro platforms that enhance the physiology of the cellular microenvironment have been developed and improved in the last decade for modeling focused properties of several tissues or organs, which are not recreated with traditional in vitro cell culture systems.
Despite published advancements in modeling tissue physiology in vitro, microphysiological systems are not yet routinely used in drug development.
FDA's initial projects have been focused on heart and liver systems and we are now expanding to other organ systems of relevance for evaluating drug effects.
Join industry leaders in a series of webinars focused on Organ-On-Chip technology
Revolutionising drug discovery. The future ofPre-Clinical Drug Research.Watch webinar